BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yang YQ, Wen ZY, Liu XY, Ma ZH, Liu YE, Cao XY, Hou L, Xie H. Current status and prospect of treatments for recurrent hepatocellular carcinoma. World J Hepatol 2023; 15(2): 129-150 [PMID: 36926237 DOI: 10.4254/wjh.v15.i2.129]
URL: https://www.wjgnet.com/2307-8960/full/v15/i2/129.htm
Number Citing Articles
1
Mingyang Du, Yonggang Qu, Lingshan Qin, Jiahe Zheng, Wei Sun. The cell death‐related genes machine learning model for precise therapy and clinical drug selection in hepatocellular carcinomaJournal of Cellular and Molecular Medicine 2024; 28(7) doi: 10.1111/jcmm.18168
2
Giulia Francesca Manfredi, Ciro Celsa, Chloe John, Charlotte Jones, Nicole Acuti, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, James Korolewicz, Matthias Pinter, Alessandra Gennari, Francesco Mauri, Mario Pirisi, Rosalba Minisini, Federica Vincenzi, Michela Burlone, Cristina Rigamonti, Matteo Donadon, Giuseppe Cabibbo, Antonio D'Alessio, David James Pinato. Mechanisms of Resistance to Immunotherapy in Hepatocellular CarcinomaJournal of Hepatocellular Carcinoma 2023; : 1955 doi: 10.2147/JHC.S291553
3
Xiaoan Qi, Liang Liu. The regulatory effect of lncRNA LINC00943 on the progression of hepatocellular carcinoma and its relationship with clinicopathological featuresClinics and Research in Hepatology and Gastroenterology 2024; 48(2): 102273 doi: 10.1016/j.clinre.2023.102273